Individualized therapy of arterial hypertension

Česká verzia

Authors: B. Nussbaumerová; H. Rosolová
Authors place of work: Centrum preventivní kardiologie, II. interní klinika LF a FN v Plzni, UK Praha
Published in the journal: Kardiol Rev Int Med 2011, 13(2): 92-95

Summary

Purely lowering blood pressure is not sufficient in up-to-date antihypertensive treatment. Certain antihypertensive drugs should be used in specific patient groups according to evidence-based medicine. The treatment should be individualized according to the risk and presence of vascular complications, concomitant diseases and life expectancy as the treatment method determined based on the patient’s individual needs is vital for the patient’s future.

Keywords:
arterial hypertension – individualized therapy – cardiovascular prevention

Zdroje

1. Widimský J Jr, Cífková R, Špinar J et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze – verze 2007. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2008; 54: 101–110, 112, 114–118.

2. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and of the European Society of Cardiology. Guidelines Committee. J Hypertens 2007; 25: 1105–1187.

3. Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121–2158.

4. The ACCORD Study Group. Eff ects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. N Engl J Med 2010; 362: 1575–1585.

5. Arima H, Chalmers J, Woodward M et al. PROGRESS Collaborative Group. Lower target blood pressure are safe and eff ective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006; 24: 1201–1208.

6. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE substudy. Lancet 2000; 355: 253–259.

7. Brenner BM, Cooper ME, de Zeeuw D et al. Effect of losartan on renal and cardiovascular outcomes in patients in type 2 diabetes and hypertension. N Engl J Med 2001; 345: 861–869.

8. The ONTARGET Investigators. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N Engl J Med 2008; 358: 1547–1559.

9. Ruggenenti P, Fassi A, Ilieva AP et al. Prevention of microalbuminuria in patients with type 2 diabetes mellitus – the BENEDICT study. N Engl J Med 2004; 351: 1941–1951.

10. De Luca A, Izzo R, Fontana D et al. Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double blind paralel study versus amlodipine. J Hypertens 2000; 18: 1515–1522.

11. Widimský P, Hlinomaz O, Kala P et al. Diagnostika a léčba akutního infarktu myokardu s elevacemi ST. Doporučení České kardiologické společnosti 2009. Cor Vasa 2009; 51: 724–740.

12. Beckett NS, Peters R, Fletcher AE et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887−1898.